Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Drops By 41.1%

Adial Pharmaceuticals, Inc. (NASDAQ:ADILGet Free Report) was the target of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 21,900 shares, a drop of 41.1% from the January 15th total of 37,200 shares. Currently, 1.5% of the company’s stock are short sold. Based on an average daily trading volume, of 95,600 shares, the days-to-cover ratio is presently 0.2 days.

Adial Pharmaceuticals Stock Performance

Shares of ADIL stock traded down $0.05 during trading on Monday, reaching $1.11. The company’s stock had a trading volume of 9,398 shares, compared to its average volume of 25,655. Adial Pharmaceuticals has a one year low of $1.05 and a one year high of $15.00. The business has a fifty day moving average price of $1.58 and a 200-day moving average price of $2.62.

Adial Pharmaceuticals (NASDAQ:ADILGet Free Report) last posted its earnings results on Tuesday, November 14th. The company reported ($1.14) EPS for the quarter, meeting the consensus estimate of ($1.14). Equities research analysts expect that Adial Pharmaceuticals will post -4.93 EPS for the current fiscal year.

Institutional Trading of Adial Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ADIL. Renaissance Technologies LLC bought a new position in Adial Pharmaceuticals in the first quarter valued at about $40,000. Virtu Financial LLC acquired a new stake in Adial Pharmaceuticals in the second quarter valued at approximately $43,000. Millennium Management LLC acquired a new position in shares of Adial Pharmaceuticals during the second quarter worth $53,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Adial Pharmaceuticals during the first quarter worth $70,000. Finally, Susquehanna International Group LLP lifted its stake in shares of Adial Pharmaceuticals by 144.3% in the 1st quarter. Susquehanna International Group LLP now owns 222,283 shares of the company’s stock valued at $78,000 after acquiring an additional 131,287 shares during the last quarter.

About Adial Pharmaceuticals

(Get Free Report)

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.

Featured Stories

Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with's FREE daily email newsletter.